APA

Derrick-Roberts A. L. K., Pyragius C. E., Kaidonis X. M., Jackson M. R., Anson D. S. & Byers S. (20150601). Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII. : Human gene therapy.

Chicago

Derrick-Roberts Ainslie L K, Pyragius Carmen E, Kaidonis Xenia M, Jackson Matilda R, Anson Donald S and Byers Sharon. 20150601. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII. : Human gene therapy.

Harvard

Derrick-Roberts A. L. K., Pyragius C. E., Kaidonis X. M., Jackson M. R., Anson D. S. and Byers S. (20150601). Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII. : Human gene therapy.

MLA

Derrick-Roberts Ainslie L K, Pyragius Carmen E, Kaidonis Xenia M, Jackson Matilda R, Anson Donald S and Byers Sharon. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII. : Human gene therapy. 20150601.